公开(公告)号：US07943176B2

公开(公告)日：2011-05-17

申请号：US10492270

申请日：2002-10-08

Applicant: Thomas Gramatte ,  Peter Gruber ,  Michael Heschel ,  Dirk Pamperin ,  Jan Ploen ,  Steffen Scheithauser ,  Wolfgang Wehner ,  Peter Guldner

Inventor： Thomas Gramatte ,  Peter Gruber ,  Michael Heschel ,  Dirk Pamperin ,  Jan Ploen ,  Steffen Scheithauser ,  Wolfgang Wehner ,  Peter Guldner

IPC: A61K9/14

CPC classification number: A61K9/2009 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/445

Abstract: By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.

Abstract translation: 通过合适的阻滞剂，可以制备含有丙哌嗪或其一种或多种药学上可接受的盐的药物组合物，其量为4mg至60mg propiverine并且具有延长的活性剂释放。 优选地，具有pKa值小于6.65的活性剂和任选的一种或多种酸性物质的混合物具有延迟涂层或嵌入基质中，然后任选地涂覆有进一步的阻滞层。

公开(公告)号：US20080317848A2

公开(公告)日：2008-12-25

申请号：US10492270

申请日：2004-04-08

Applicant: Thomas Gramatte ,  Peter Gruber ,  Michael Heschel ,  Dirk Pamperin ,  Jan Ploen ,  Steffen Scheithauer ,  Wolfgang Wehner ,  Peter Guldner

Inventor： Thomas Gramatte ,  Peter Gruber ,  Michael Heschel ,  Dirk Pamperin ,  Jan Ploen ,  Steffen Scheithauer ,  Wolfgang Wehner ,  Peter Guldner

IPC: A61K31/445 ,  A61K9/20

CPC classification number: A61K9/2009 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/445

Abstract: By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.

Abstract translation: 通过合适的阻滞剂，可以制备含有丙哌嗪或其一种或多种药学上可接受的盐的药物组合物，其量为4mg至60mg propiverine并且具有延长的活性剂释放。 优选地，具有pKa值小于6.65的活性剂和任选的一种或多种酸性物质的混合物具有延迟涂层或嵌入基质中，然后任选地涂覆有进一步的阻滞层。